A cognitively unimpaired person with biomarker evidence of both amyloid and tau would be diagnosed with “preclinical AD” according to the NIA-AA research criteria, but be diagnosed as “at risk for progression to prodromal AD or AD dementia” under the new IWG guidelines [16, 17]. This evidence concerns the gene MAPT and Alzheimer disease.